Alchemy Pay adds StraitsX $XSGD and $XUSD to its fiat on-ramp, letting users in 173 countries buy them with cards, bank transfers and mobile wallets.Alchemy Pay adds StraitsX $XSGD and $XUSD to its fiat on-ramp, letting users in 173 countries buy them with cards, bank transfers and mobile wallets.

Alchemy Pay Lists StraitsX Stablecoins to Expand Global Fiat-to-Crypto Access

alchemypay

Alchemy Pay has given users around the world a simpler way to move cash onto blockchains by adding StraitsX’s $XSGD and $XUSD stablecoins to its fiat on-ramp. The payment gateway, already known for connecting traditional payment rails to crypto networks, now lets people in 173 countries buy these fiat-backed tokens with familiar methods like Visa and Mastercard, Apple Pay and Google Pay, local bank transfers and mobile wallets across more than 50 fiat currencies.

That might sound technical, but the practical effect is straightforward: people and businesses who want stable, regulator-friendly crypto exposure can now convert local currency into $XSGD and $XUSD without jumping through hoops. For many users, especially institutions that care about compliance and settlement certainty, this removes a major friction point between bank accounts and stablecoins.

StraitsX positions itself as a settlement layer built for stablecoins. Its $XSGD and $XUSD are fully reserved, fiat-backed tokens intended to make cross-border payments and liquidity flows smoother. Importantly, both coins are recognised by the Monetary Authority of Singapore as being substantively compliant with the regulator’s forthcoming Single-Currency Stablecoin framework, a signal that they were designed with oversight and real-world integration in mind. StraitsX also works with established banks such as Standard Chartered and DBS, which helps the project stitch together traditional finance and on-chain liquidity.

Faster Fiat-to-Crypto Flows

For Alchemy Pay, the listing is part of a broader push to mainstream crypto payments. The company has built a global network underpinned by an array of regulatory approvals, including ten U.S. Money Transmitter Licenses and permissions across Southeast Asia, Korea, Europe and the U.K. That licensing footprint matters: it gives payment partners and customers confidence that when they move fiat into the crypto world, those flows meet regulatory expectations.

Behind the scenes, Alchemy Pay is also building new infrastructure of its own. The company is developing Alchemy Chain, a Layer-1 blockchain focused on stablecoin payments, and plans to launch a testnet soon alongside its own stablecoin. That roadmap suggests Alchemy Pay sees the future of payments as a mix of traditional rails and purpose-built blockchain layers working together.

The addition of $XSGD and $XUSD broadens the choices available to users who want a compliant path into digital currencies. It’s a reminder that the stablecoin ecosystem is maturing: issuers are working with banks and regulators, and payment gateways are trying to make on-ramps as seamless as possible. For end users, this means fewer steps, less confusion, and a clearer route from everyday money to programmable money. This integration is expected to accelerate adoption by firms and consumers seeking reliable digital payment options.

As stablecoins become more central to cross-border transactions and digital commerce, partnerships like the one between Alchemy Pay and StraitsX illustrate a simple idea playing out in the market: when regulated issuers and established payment providers cooperate, moving between fiat and crypto stops feeling like a technical stunt and starts feeling like an everyday utility.

Market Opportunity
Lorenzo Protocol Logo
Lorenzo Protocol Price(BANK)
$0,05387
$0,05387$0,05387
+1,35%
USD
Lorenzo Protocol (BANK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26